Advertisement
New Zealand markets closed

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NZD/USD

    0.5951
    +0.0002 (+0.03%)
     

  • NZD/EUR

    0.5550
    +0.0010 (+0.18%)
     

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • OIL

    84.04
    +0.47 (+0.56%)
     

  • GOLD

    2,357.00
    +14.50 (+0.62%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,114.48
    +35.62 (+0.44%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,043.83
    +126.55 (+0.71%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • NZD/JPY

    93.2870
    +0.7910 (+0.86%)
     

Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

Alex Carchidi, The Motley Fool
·5-min read
Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

Most pharma investors are familiar with power players like Eli Lilly (NYSE: LLY) and Bristol Myers Squibb, (NYSE: BMY) and both businesses have a lot to offer passive income investors too. As one of the world's most preeminent pharma conglomerates, Eli Lilly and its portfolio of products covers all sorts of illnesses, including Alzheimer's disease, diabetes, and different cancers. It also has 21 programs in phase 3 clinical trials, and another 21 in phase 2 trials.

Continue reading